Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag.filedCriticalF.Hoffmann-La Roche Ag.
Publication of YU9302ApublicationCriticalpatent/YU9302A/en
The use of therapeutically effective amount of IFN- α or PEG-IFN-α in association with a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid for the manufacture of medicaments for treating liver diseases patients. The components are administered over a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies/ml at 24 weeks after the end of treatment.
YU9302A1999-08-132000-08-08Mycophenolate mofetil in association with peg-ifn-alpha
YU9302A
(en)
Pharmaceutical composition process for providing an antihistamine treatment which does not induce any significant cardiac arrhythmia in a human patient and use of a composition for the manufacture of a medicine for use in an antihistamine treatment
Method of reducing blood cholesterol and / or other blood glycerides in a mammal individual, preparation in the form of a dosage unit, and, set to orally administer the same